olivier Charmeil

About olivier Charmeil

Olivier Charmeil is a seasoned French executive in the healthcare and pharmaceutical sector, best known for his senior leadership roles at Sanofi and as a board member of genOway. He graduated from HEC Paris and the Institut d’Études Politiques in Paris, and began his career in the mergers and acquisitions department of Banque de l’Union Européenne before joining Sanofi in 1994. That combination of financial and industrial exposure gave him a profile well suited to the governance and strategic demands of large, regulated healthcare companies. At Sanofi, Charmeil built a long and progressive career across several key businesses and geographies. He joined the Executive Committee in 2011 when he was appointed head of Sanofi Pasteur. He later held a range of group responsibilities, including leadership over China and Emerging Markets, before taking charge of the General Medicines unit. Sanofi describes this division as a diversified portfolio of iconic brands and essential medicines used by patients with chronic conditions, and notes that he has focused on innovation, digital tools and more sustainable healthcare systems. His expertise spans international strategy, operational execution in highly regulated environments, business transformation, and the leadership of complex product portfolios. In June 2020, he was appointed to the board of the European Federation of Pharmaceutical Industry Associations (EFPIA), strengthening his influence within European pharma representation. He also became a director of genOway in 2022. genOway said his nomination would bring nearly 30 years of healthcare experience, insight into pharmaceutical research trends, and a strong innovation mindset to support the company’s ongoing strategic repositioning toward higher-margin activities, including its catalog model offering in immuno-oncology. In the ecosystem of listed and research-intensive healthcare companies, Charmeil stands out for his group-wide credibility, international perspective, and ability to link scientific innovation with disciplined governance and value creation. His career shows the hallmarks of a leader able to support biotech and pharmaceutical businesses through strategic transformation, growth, and long-term performance improvement.